Roth/MKM Initiates Buy Rating on vTv Therapeutics Amid Optimism for Diabetes Treatment
Roth/MKM has begun coverage of vTv Therapeutics with a Buy rating and a target price of $58, citing promising prospects for the company's oral diabetes treatment cadisegliatin. Anticipated Phase 3 data and ongoing clinical developments reinforce a positive outlook despite current unprofitability, with key financial and patent details supporting ope…